Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 218,355,180 papers from all fields of science
Search
Sign In
Create Free Account
LF 150195
Known as:
LF 15-0195
, LF-15-0195
, LF15-0195
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
Guanidines
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Is there B cell involvement in a rat model of spontaneous idiopathic nephrotic syndrome treated with LF15-0195?
L. Le Berre
,
G. Tilly
,
J. Dantal
JN. Journal of Nephrology (Milano. )
2014
Corpus ID: 21138859
BackgroundThe Buffalo/Mna (Buff/Mna) rat spontaneously develops idiopathic nephrotic syndrome (INS), and its nephropathy recurs…
Expand
Highly Cited
2002
Highly Cited
2002
Induction of Donor‐Specific Allograft Tolerance by Short‐Term Treatment with LF15‐0195 After Transplantation. Evidence for a Direct Effect on T‐Cell Differentiation
Elise Chiffoleau
,
G. Beriou
,
P. Dutartre
,
C. Usal
,
J. Soulillou
,
M. Cuturi
American Journal of Transplantation
2002
Corpus ID: 24723097
A 20‐day treatment with LF15–0195, a deoxyspergualine analog, induced long‐term heart allograft survival in the rat without signs…
Expand
Highly Cited
2002
Highly Cited
2002
Role for Thymic and Splenic Regulatory CD4+ T Cells Induced by Donor Dendritic Cells in Allograft Tolerance by LF15-0195 Treatment1
Elise Chiffoleau
,
G. Beriou
,
P. Dutartre
,
C. Usal
,
J. Soulillou
,
M. Cuturi
Journal of Immunology
2002
Corpus ID: 24736625
A 20-day treatment with LF15-0195, a deoxyspergualine analogue, induced allograft tolerance in a fully MHC-mismatched heart…
Expand
2000
2000
A NOVEL IMMUNOSUPPRESSANT, LF15-0195c, PREVENTS THE DEVELOPMENT OF ANTI-GBM DISEASE IN RATS
Tesch Gh
,
W. Mu
,
+4 authors
R. Atkins
2000
Corpus ID: 72980143
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE